124 Views

Demystifying MRD with BloodPac: Navigating Clinical and Technical Pathways for Comprehensive Cancer Monitoring

Wednesday, November 12, 2025

4:00 PM - 4:50 PM EST

Location: 156AB, Level 1

Corporate Workshop Panelist(s)

LL

Lauren Leiman

Executive Director
BLOODPAC
TP

Traci Pawlowski, PhD

VP, Head Clinical Solutions
Illumina
AP

Aparna R. Parikh, MD

Associate Professor, Medicine
Harvard Medical School
JB

Jonathan Beer

Senior Director, Precision Medicine Lead
Bristol Myers Squibb
JG

Jim Godsey, PhD

Scientific Co-Chair Committee
BLOODPAC

Minimal Residual Disease (MRD) testing is transforming cancer care, yet significant variability remains across technologies, indications, and clinical integration. This panel brings together experts from both industry and clinic to demystify MRD testing, discuss emerging best practices, and provide guidance on clinical and technical considerations. The session will explore indication-specific requirements, the emerging value of whole genome sequencing (WGS)-based MRD approaches, and the evolving debate between tissue-informed and tissue-agnostic strategies. Attendees will gain practical insights into optimizing MRD testing workflows to enhance patient outcomes, while aligning with regulatory, scientific, and clinical standards. 